Comparative Pharmacology
Head-to-head clinical analysis: NEBIVOLOL HYDROCHLORIDE versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBIVOLOL HYDROCHLORIDE versus TRASICOR.
NEBIVOLOL HYDROCHLORIDE vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist with nitric oxide-mediated vasodilatory activity via stimulation of beta-3 receptors.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
5 mg orally once daily. May be initiated at 2.5 mg in patients with renal impairment or those at risk of hypotension. Titrate at 2-week intervals up to 40 mg once daily.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-19 hours in extensive metabolizers; up to 30-50 hours in poor CYP2D6 metabolizers; clinically, once-daily dosing is effective due to pharmacodynamic half-life >40 hours.
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Approximately 38% renal, 48% fecal (unchanged drug and metabolites); extensive hepatic metabolism (CYP2D6) with glucuronidation; <1% excreted unchanged in urine.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker